Healthcare, the second-largest sector weight in the S&P 500, was the best-performing sector in the U.S. last year and that strength is carrying over to 2019. The Health Care Select Sector SPDR ETF (NYSEArca: XLV), the largest healthcare ETF by assets, is up 4.13% to start the new year.
XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks. There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up. Consequently, investors may also turn to defensive sectors that are less economically sensitive, such as health care.
“While analysts have downgraded S&P 500® Index earnings for 2019, earnings growth in the Heath Care sector remains intact on the back of stable demand and strong product pipeline,” said State Street in a recent note.
Industry observers argue that medical technology companies can tap into increased healthcare spending among emerging economies while the U.S. market has matured and could experience slower growth. Looking ahead, in the years through 2024, spending growth is projected to average 5.8% and peak at 6.3% in 2020.
More Catalysts
Increased drug approvals could be another factor boosting XLV and rival healthcare ETFs this year.